Clinical trials have demonstrated that blockade of the interactions between PD-1 and PD-L1 enhances anticancer immunity in SCLC, thus leading to a potentially-improved progression-free survival (PFS) and OS [22,23,24]. The gene discussed is CD274; the disease is small cell lung carcinoma.